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ABSTRACT
Introduction: Mortality in patients with cystic
fibrosis-related diabetes (CFRD) is higher than
that in patients with cystic fibrosis without
diabetes. Hypoglycemia, hyperglycemia, and
glucose variability confer excess mortality and
morbidity in the general inpatient population
with diabetes.
Methods: We investigated patterns of
hypoglycemia and the association of
hypoglycemia, hyperglycemia, and glucose
variability with mortality and readmission rate
in inpatients with CFRD. All capillary blood
glucose (CBG) readings (measured using the
Abbott Precision web system) of patients with
insulin-treated CFRD measured within our
health board between January 2009 and
January 2015 were. Frequency and timing of
hypoglycemia (\4 mmol/L) and was recorded.
The effect of dysglycemia on readmission and
mortality was investigated with survival
analysis.
Results: Sixty-six patients were included. A
total of 22,711 CBG results were included in
the initial analysis. Hypoglycemia was common
with 1433 episodes (6.3%). Hypoglycemia
ascertainment was highest between 2400 and
0600 h. Hypoglycemia was associated with a
significantly higher rate of readmission or death
over the 3.5-year follow-up period (P = 0.03).
There was no significant association between
hyperglycemia or glucose variability and the
rate of readmission and mortality.
Conclusion: Among inpatients with CFRD
hypoglycemia is common and is associated
with an increased composite endpoint of
readmission and death. As with previously
reported trends in general inpatient
population this group shows a peak incidence
of hypoglycemic during the night.
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INTRODUCTION
Cystic fibrosis (CF) is a multi-organ disease
caused by mutations in the CF transmembrane
conductance regulator gene that which lead to
ineffective clearance of secretions from
epithelial surfaces [1]. The pancreas is one of
the main organs affected. A large proportion of
patients will require pancreatic enzyme
replacement therapy for the damaged exocrine
functions of their pancreas. According to the
2014 report of the UK Cystic Fibrosis Registry,
18.3% of UK patients with CF have a diagnosis
of CF-related diabetes (CFRD) [2]. This
percentage is likely to increase with increased
longevity of patients with CF, as up to 47.5% of
adult patients with CF have a significant glucose
metabolism impairment [3].
The annual mortality rate among patients
with CF in the UK is 1.5% [2], but in CF patients
with a diagnosis of CFRD the mortality rate
increases by threefold [4]. Insulin therapy has
consequently been advocated to ameliorate the
poor outcome associated with CFRD based on
its proposed positive impact on the lung
function of patients diagnosed with CFRD, as
well as its ability to alleviate the rate of decline
in pulmonary function tests (PFTs). Patients are
occasionally started on insulin therapy in the
absence of fasting hyperglycemia or at the
impaired glucose tolerance stage when
impaired first-phase insulin release causes high
post-prandial glucose [5]. As well as impacting
on PFTs, the reduction in postprandial glucose
excursions with insulin therapy is thought to
help increase body weight. This approach is not
without risk as the use of insulin is associated
with an increased rate of hypoglycemia [5].
Previous studies have shown that
hypoglycemia, hyperglycemia, and glucose
variability are additional risk factors for
mortality and morbidity in the general
inpatient population with diabetes [6–8]. We
are not aware of any published study looking at
the impact of these glucometric parameters on
inpatients with a diagnosis of CF. The aim of
this study was, therefore, to investigate
patterns, frequency, and trends of
hypoglycemia in the insulin-treated CF
population of the National Health Service
Greater Glasgow and Clyde (NHSGGC). We
also investigated the association between
hypoglycemia, hyperglycemia, and glucose
variability, with morbidity (as measured by
readmission rates) and mortality.
METHODS
All patientswithCFwhosehealthcareneedswere
provided by theNHSGGCHealth Board and their
Community Health Index were identified.
Individuals with inpatient capillary blood
glucose (CBG) measurements that had been
uploaded to the Precision Web Point-of-Care
DataManagement System (Abbott Diabetes Care
Inc., Alameda, CA) during the time period
January 2009 to January 2015 were identified
and the data retrieved.
The analysis of CBG data involved linking
these data to mortality datasets. Data on insulin
use was obtained from the local departmental
CF database. Dates of admission and discharge
were identified from CBG data. The incidence
and timing of biochemical hypoglycemia
(defined as a recorded CBG value if\4 mmol/
L) and hyperglycemia (defined as a recorded
CBG value of [15 mmol/L) were identified
during an index admission—defined as the
first admission occurring during the study
period. The interquartile range (IQR) of
inpatient CBG values was calculated for each
admission.
The association between the incidence of one
or more episodes of hypoglycemia and a
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composite endpoint of time to first readmission
or death following the index admission (date of
discharge to date of readmission or death) was
investigated. The impact of incidence of
hyperglycemia was similarly explored.
Association of the IQR (top 50% vs. lower 50%)
with first readmission or death was calculated.
Additionally, the proportion of measured CBG
values that were within the hypoglycemic range
during a nocturnal time period (2400–0600
hours) versus daytime (0600–2400 hours) was
calculated and compared to that of the daytime
period (0600–2400 hours).
Statistical analysis of data was performed
using R, a statistical computing environment
[9]. Survival analysis was analyzed using the
Cox proportional hazards model, including age
at admission and duration of admission as
covariables. The Chi-square test was used to
compare the number of CBG measurements
that were\4 mmol/L as a proportion of all CBG
measurements performed during the daytime
and nocturnal time periods.
This study was conducted in accordance
with the Declaration of Helsinki. Informed
consent was not required for this study.
RESULTS
A total of 291 patients with CF whose
healthcare was provided by the NHSGGC
Health Board were identified. Of all patients
with CF, 126 had one or more CBG readings
performed during the period of analysis. We
identified a total of 1014 admission episodes
and 22,711 CBG measurements for this group.
Of these 126 patients, 66 were recorded as both
receiving insulin therapy and having been
admitted during the period of investigation.
These latter 66 patients were included in the
analysis and their characteristics are described
in Table 1.
Hypoglycemia was common within the total
CF inpatient population on insulin, with 1433
CBG values (6.3%) recorded within the
hypoglycemic range across all admissions. The
proportion of CBG measurements below the
threshold for hypoglycemia in patients with CF
on insulin therapy was higher during the
nighttime (2400–0600; P\0.01; Fig. 1).
Of the 66 patients included in the study, 64
(97%) were readmitted or died following the
index admission during the follow-up period.
Table 1 Characteristics of insulin-treated patients with cystic ﬁbrosis-related diabetes included in study
Characteristics Value Number of patients for
whom data are available
Age (years) 29 [23.0–35.0] 66
BMI (kg/m2) 20.7 [19.0–22.3] 51
Male 0.58 (38) 66
FEV1 (L) 50.0 [29.3–59.8] 46
FVC (L) 68.0 [55.5–81.0] 46
Readmitted post-index admission 0.95 (63) 66
Mortality during follow-up period 0.32 (21) 66
Values in table are presented as the median with the interquartile range (IQR) in square brackets or as the proportion with
the number in parenthesis, as appropriate
IQR interquartile range, BMI Body mass index, FEV1 forced expiratory volume in the ﬁrst second, FVC forced vital capacity
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Thirty-three individuals had a hypoglycemic
event during the index admission. Baseline and
admission characteristics of those patients with
and without hypoglycemia are shown in
Table 2. There was no significant difference
between the two groups when age, body mass
index (BMI), forced expiratory volume in the
first second (FEV1), forced vital capacity (FVC),
or median number of CBG tests performed per
day were compared by the t test. There was a
significantly greater proportion of males
admitted who did not suffer a hypoglycemic
Fig. 1 Proportion of all capillary blood glucose (CBG) measurements that were within the hypoglycemic range (\4 mmol/
L) by hour of day
Table 2 Characteristics of cystic ﬁbrosis patients with and without recorded hypoglycemia
Characteristics Hypoglycemia during admission No hypoglycemia during admission P value
Value Number of patients
for whom data are
available
Value Number of patients
for whom data are
available
Age (years) 29 [23–34] 33 28 [23–36] 33 0.7
BMI (kg/m2) 20.2 [19.2–22.0] 24 21.3 [18.6–22.8] 27 0.3
Male 0.42 33 0.73 33 0.02*
FEV1 50 [30–59] 21 50 [29–60] 25 0.3
FVC 65 [55–71] 21 72 [57–82] 25 0.1
Number of CBG
measurements per day
3.8 [2.7–5.5] 33 4.7 [3.0–12.2] 33 0.4
Values in table are presented as the median with the IQR in square brackets or as the proportion, as appropriate
CBG Capillary blood glucose
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event. Of these, all (100%) were readmitted or
died during the follow-up period, whereas 31 of
33 (94%) individuals without hypoglycemia
were readmitted or died. Median time to
readmission or death was 94 [95% confidence
interval (CI) 69–161] days for those with
hypoglycemia versus 219 (95% CI 129–340)
days for those without. The occurrence of
hypoglycemia was associated with a significant
difference in time to first readmission or death
on the survival analysis, with age and admission
duration as covariables (P = 0.03; Fig. 2).
There was no significant association between
hyperglycemia and time to first readmission or
death, with a median time to the endpoint of
102 (95% CI 85–269) days in the hyperglycemia
cohort and 149 (95% CI 108–282) days in the
cohort without hyperglycemia (P = 0.60 on
survival analysis). No difference in time to
endpoint was observed in those individuals
with high glucose variability (IQR values in
the upper 50% of all IQR values when compared
with those in the lower 50%; P = 0.34).
No significant excess mortality was identified
in those with hypoglycemia (13/33, 39%) versus
those without (8/33, 24%; P = 0.47 on survival
analysis) and in those with hyperglycemia (10/
21, 48%) versus those without (11/45, 24%;
P = 0.32).
DISCUSSION
Identified biochemical hypoglycemia occurs
more frequently in the inpatient population
with insulin-treated CFRD than in the wider
inpatient population with diabetes. In this
study, 6.1% of the CBG measurements were in
the hypoglycemic range, compared to 4.1% in a
general diabetic population studied using the
same methodology [9]. The higher rate of
hypoglycemia seen in this group is likely to be
due to the insulin therapy which all patients
entered into our study were receiving. Local
standard practice consists of a basal bolus
regime with basal and prandial insulin
analogs, as guided by the CBG measurements.
Hypoglycemia may also be more common in
the CFRD group secondary to diminished
exocrine pancreatic function, with
malabsorption, loss of glucagon response, and
Fig. 2 Survival analysis to death or over a 3.5-year follow-up period. Group with recorded hypoglycemia during admission
(broken red line) was compared to the group without hypoglycemia (solid black line). HR Hazard ratio
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reduced hypoglycemia awareness in patients
with CFRD [10]. As with the general population
with diabetes, hypoglycemia is more frequent
during the nighttime [9]. This is potentially
important as overnight CBG testing is often not
part of routine diabetes management. It has
previously been shown that a significant burden
of nocturnal hypoglycemia is likely to be
unrecorded secondary to the sporadic nature
of overnight testing [9].
We have shown that hypoglycemia is
associated with a significant increase in the
rate of the composite endpoint of readmission
and death over a 3.5-year follow-up period.
With only one death occurring before the first
readmission in this group, this finding is driven
mainly by the increased rate of readmission.
Hypoglycemia was associated with a
non-significant increase in overall mortality. It
is possible that episodes of hypoglycemia cause
direct harm or predict a tendency for future
deleterious hypoglycemic episodes causing
adverse outcome. While no significant
difference in available baseline characteristics
or frequency of CBG testing were observed
between those patients with and without
hypoglycemia, it is likely that patients who are
more ill and thereby readmitted more quickly
have greater degrees of sepsis, liver disease,
debility, and physiological derangement and
are, therefore, more prone to hypoglycemia.
In our dataset, hyperglycemia and glucose
variability did not show a significant association
with readmission or mortality. In general,
studies on diabetes inpatient populations have
reported that hypoglycemia, hyperglycemia,
and increased glucose variability are associated
with excess morbidity and mortality [6–8]. It is
likely that our dataset is underpowered to show
any statistically significant increase in mortality
associated with hypoglycemia, hyperglycemia,
or glucose variability in this patient group.
Most of the hypoglycemic episodes were
noted at the times when routine blood sugar
monitoring was performed on the ward, which
happens four times daily in our unit. This
observation suggests that there may be a
significant burden of hypoglycemia at other
times of the day when CBG is not being tested.
As hypoglycemia has been shown to confers
excess mortality in the general inpatient
population with diabetes, this possibility may
be of clinical importance [6, 7].
This study had several limitations.
Information gathering was difficult despite the
introduction of electronic notes and the
diabetes database (SCI-Diabetes). The dataset is
quite small and heterogeneous, with patients
having been started on insulin who have both
impaired glucose tolerance and CFRD. We also
lack data on other potential markers of poor
outcome, such as sepsis, steroid use, enteral
feeding, and transplantation. A larger,
multi-center prospective study is required to
determine whether the suspected trends of
increased morbidity and mortality observed in
this study are indeed significant. While
individuals with CF are known to die earlier if
they have diabetes, we do not have the data that
would verify the benefit of tight glycemic
control in CFRD or delineate fully the possible
adverse outcomes [11].
CONCLUSIONS
Recommendations for Practice
A seven-point profile of blood sugar
monitoring should be considered in
inpatients with CF on insulin therapy, rather
than the standard four-point profile. Patients
with CF on insulin represent a high-risk group
who experience fluctuations in their glycemic
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control due to respiratory infections,
concurrent steroid use, and physical stress. A
seven-point profile will facilitate the
identification of patients with hypoglycemia
and postprandial hyperglycemia more readily.
Doses of insulin can then be adjusted in a
timely and accurate manner.
This study highlights the need for adequate
resources dedicated to specialist diabetes input
to inpatients with CFRD. Appropriate training
and access to guidelines should also be in place
for all medical staff and ward nurses who are in
charge of the day-to-day prescription and
administration of insulin to this group of
vulnerable patients.
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